OneStudyTeam valuation, funding and investors
OneStudyTeam works in clinical trial management software development, based in Boston, United States. Founded in 2012, it has about 78 employees.
- Last round
- Series D · $220M · Apr 2022
- Valuation at last round
- $4.80B
- Headcount
- 78 · flat
- Grade
- D
- Founded
- 2012
OneStudyTeam valuation today
VCMC values OneStudyTeam at $3.2B today, with a range of $341M to $6.3B and a grade of D. The valuation starts from its last funding round, a Series D round in Apr 2022.
Valuation by date (183 rows)
Each point is what the model would have shown on that date, using only what was known then; before its first round, a company is valued as a startup because it later raised.
| Date | Valuation | Range | Predicted in 1 yr | Phase | Headcount | Trend | Grade | Winding-down probability |
|---|---|---|---|---|---|---|---|---|
| 1 Jan 2012 | $4.60M | $1.67M – $12.6M | $4.70M (+2%) | before first round | – | unknown | D | 0% |
| 1 Feb 2012 | $4.60M | $1.67M – $12.6M | $4.72M (+3%) | before first round | – | unknown | D | 0% |
| 1 Mar 2012 | $4.60M | $1.67M – $12.6M | $4.74M (+3%) | before first round | – | unknown | D | 0% |
| 1 Apr 2012 | $4.60M | $1.67M – $12.6M | $4.76M (+4%) | before first round | – | unknown | D | 0% |
| 1 May 2012 | $4.60M | $1.67M – $12.6M | $4.78M (+4%) | before first round | – | unknown | D | 0% |
| 1 Jun 2012 | $4.60M | $1.67M – $12.6M | $4.80M (+4%) | before first round | – | unknown | D | 0% |
| 1 Jul 2012 | $4.60M | $1.67M – $12.6M | $4.82M (+5%) | before first round | – | unknown | D | 0% |
| 1 Aug 2012 | $4.61M | $1.68M – $12.7M | $4.84M (+5%) | before first round | – | unknown | D | 0% |
| 1 Sep 2012 | $4.63M | $1.69M – $12.7M | $4.85M (+5%) | before first round | – | unknown | D | 0% |
| 1 Oct 2012 | $4.65M | $1.69M – $12.8M | $4.87M (+5%) | before first round | – | unknown | D | 0% |
| 1 Nov 2012 | $4.67M | $1.70M – $12.8M | $4.89M (+5%) | before first round | – | unknown | D | 0% |
| 1 Dec 2012 | $4.69M | $1.71M – $12.9M | $4.91M (+5%) | before first round | – | unknown | D | 0% |
| 1 Jan 2013 | $4.70M | $1.71M – $12.9M | $4.93M (+5%) | before first round | – | unknown | D | 0% |
| 1 Feb 2013 | $4.72M | $1.72M – $13.0M | $4.95M (+5%) | before first round | – | unknown | D | 0% |
| 1 Mar 2013 | $4.74M | $1.73M – $13.0M | $4.97M (+5%) | before first round | – | unknown | D | 0% |
| 1 Apr 2013 | $4.76M | $1.73M – $13.1M | $4.99M (+5%) | before first round | – | unknown | D | 0% |
| 1 May 2013 | $4.78M | $1.74M – $13.1M | $5.01M (+5%) | before first round | – | unknown | D | 0% |
| 1 Jun 2013 | $4.80M | $1.75M – $13.2M | $5.03M (+5%) | before first round | – | unknown | D | 0% |
| 1 Jul 2013 | $4.82M | $1.75M – $13.2M | $5.05M (+5%) | before first round | – | unknown | D | 0% |
| 1 Aug 2013 | $4.83M | $1.76M – $13.3M | $5.07M (+5%) | before first round | – | unknown | D | 0% |
| 1 Sep 2013 | $4.85M | $1.77M – $13.3M | $5.09M (+5%) | before first round | – | unknown | D | 0% |
| 1 Oct 2013 | $4.87M | $1.77M – $13.4M | $5.11M (+5%) | before first round | – | unknown | D | 0% |
| 1 Nov 2013 | $4.89M | $1.78M – $13.4M | $5.13M (+5%) | before first round | – | unknown | D | 0% |
| 1 Dec 2013 | $4.91M | $1.79M – $13.5M | $5.15M (+5%) | before first round | – | unknown | D | 0% |
| 1 Jan 2014 | $4.93M | $1.79M – $13.5M | $5.17M (+5%) | before first round | – | unknown | D | 0% |
| 1 Feb 2014 | $4.95M | $1.80M – $13.6M | $5.19M (+5%) | before first round | – | unknown | D | 0% |
| 1 Mar 2014 | $4.97M | $1.81M – $13.6M | $5.21M (+5%) | before first round | – | unknown | D | 0% |
| 1 Apr 2014 | $4.99M | $1.82M – $13.7M | $5.23M (+5%) | before first round | – | unknown | D | 0% |
| 1 May 2014 | $5.01M | $1.82M – $13.8M | $5.25M (+5%) | before first round | – | unknown | D | 0% |
| 1 Jun 2014 | $5.03M | $1.83M – $13.8M | $5.27M (+5%) | before first round | – | unknown | D | 0% |
| 1 Jul 2014 | $5.05M | $1.84M – $13.9M | $5.29M (+5%) | before first round | – | unknown | D | 0% |
| 1 Aug 2014 | $5.07M | $1.84M – $13.9M | $5.31M (+5%) | before first round | – | unknown | D | 0% |
| 1 Sep 2014 | $5.09M | $1.85M – $14.0M | $5.33M (+5%) | before first round | – | unknown | D | 0% |
| 1 Oct 2014 | $5.11M | $1.86M – $14.0M | $5.35M (+5%) | before first round | – | unknown | D | 0% |
| 1 Nov 2014 | $5.13M | $1.87M – $14.1M | $5.37M (+5%) | before first round | – | unknown | D | 0% |
| 1 Dec 2014 | $5.15M | $1.87M – $14.1M | $5.39M (+5%) | before first round | – | unknown | D | 0% |
| 1 Jan 2015 | $5.17M | $1.88M – $14.2M | $5.41M (+5%) | before first round | – | unknown | D | 0% |
| 1 Feb 2015 | $5.19M | $1.89M – $14.2M | $5.44M (+5%) | before first round | – | unknown | D | 0% |
| 1 Mar 2015 | $5.21M | $1.90M – $14.3M | $5.46M (+5%) | before first round | – | unknown | D | 0% |
| 1 Apr 2015 | $5.23M | $1.90M – $14.4M | $5.48M (+5%) | before first round | – | unknown | D | 0% |
| 1 May 2015 | $5.25M | $1.91M – $14.4M | $5.50M (+5%) | before first round | – | unknown | D | 0% |
| 1 Jun 2015 | $5.27M | $1.92M – $14.5M | $5.52M (+5%) | before first round | – | unknown | D | 0% |
| 1 Jul 2015 | $5.29M | $1.93M – $14.5M | $5.54M (+5%) | before first round | – | unknown | D | 0% |
| 1 Aug 2015 | $5.31M | $1.93M – $14.6M | $5.69M (+7%) | before first round | – | unknown | D | 0% |
| 1 Sep 2015 | $5.33M | $1.94M – $14.6M | $5.84M (+10%) | before first round | – | unknown | D | 0% |
| 1 Oct 2015 | $5.35M | $1.95M – $14.7M | $5.99M (+12%) | before first round | – | unknown | D | 0% |
| 1 Nov 2015 | $5.37M | $1.96M – $14.8M | $6.16M (+15%) | before first round | – | unknown | D | 0% |
| 1 Dec 2015 | $5.39M | $1.96M – $14.8M | $6.32M (+17%) | before first round | – | unknown | D | 0% |
| 1 Jan 2016 | $5.41M | $1.97M – $14.9M | $6.49M (+20%) | before first round | – | unknown | D | 0% |
| 1 Feb 2016 | $5.44M | $1.98M – $14.9M | $6.67M (+23%) | before first round | – | unknown | D | 0% |
| 1 Mar 2016 | $5.46M | $1.99M – $15.0M | $6.84M (+25%) | before first round | – | unknown | D | 0% |
| 1 Apr 2016 | $5.48M | $1.99M – $15.0M | $7.02M (+28%) | before first round | – | unknown | D | 0% |
| 1 May 2016 | $5.50M | $2.00M – $15.1M | $7.21M (+31%) | before first round | – | unknown | D | 0% |
| 1 Jun 2016 | $5.52M | $2.01M – $15.2M | $7.40M (+34%) | before first round | – | unknown | D | 0% |
| 1 Jul 2016 | $5.54M | $2.02M – $15.2M | $7.60M (+37%) | before first round | – | unknown | D | 0% |
| 1 Aug 2016 | $5.69M | $2.07M – $15.6M | $7.80M (+37%) | before first round | – | unknown | D | 0% |
| 1 Sep 2016 | $5.84M | $2.13M – $16.1M | $8.01M (+37%) | before first round | – | unknown | D | 0% |
| 1 Oct 2016 | $6.00M | $2.18M – $16.5M | $8.22M (+37%) | before first round | – | unknown | D | 0% |
| 1 Nov 2016 | $6.16M | $2.24M – $16.9M | $8.45M (+37%) | before first round | – | unknown | D | 0% |
| 1 Dec 2016 | $6.32M | $2.30M – $17.4M | $8.67M (+37%) | before first round | – | unknown | D | 0% |
| 1 Jan 2017 | $6.49M | $2.36M – $17.8M | $8.90M (+37%) | before first round | – | unknown | D | 0% |
| 1 Feb 2017 | $6.67M | $2.43M – $18.3M | $9.14M (+37%) | before first round | – | unknown | D | 0% |
| 1 Mar 2017 | $6.83M | $2.49M – $18.8M | $9.36M (+37%) | before first round | – | unknown | D | 0% |
| 1 Apr 2017 | $7.01M | $2.55M – $19.3M | $9.62M (+37%) | before first round | – | unknown | D | 0% |
| 1 May 2017 | $7.20M | $2.62M – $19.8M | $9.87M (+37%) | before first round | – | unknown | D | 0% |
| 1 Jun 2017 | $7.39M | $2.69M – $20.3M | $10.1M (+37%) | before first round | – | unknown | D | 0% |
| 1 Jul 2017 | $7.59M | $2.76M – $20.8M | $10.4M (+37%) | before first round | – | unknown | D | 0% |
| 1 Aug 2017 | $7.79M | $2.84M – $21.4M | $10.7M (+37%) | before first round | – | unknown | D | 0% |
| 1 Sep 2017 | $8.01M | $2.91M – $22.0M | $11.0M (+37%) | before first round | – | unknown | D | 0% |
| 1 Oct 2017 | $8.22M | $2.99M – $22.6M | $11.3M (+37%) | before first round | – | unknown | D | 0% |
| 1 Nov 2017 | $8.44M | $3.07M – $23.2M | $11.6M (+37%) | before first round | – | unknown | D | 0% |
| 1 Dec 2017 | $8.66M | $3.15M – $23.8M | $11.9M (+37%) | before first round | – | unknown | D | 0% |
| 1 Jan 2018 | $8.90M | $3.24M – $24.4M | $12.2M (+37%) | before first round | – | unknown | D | 0% |
| 1 Feb 2018 | $9.14M | $3.33M – $25.1M | $12.5M (+37%) | before first round | – | unknown | D | 0% |
| 1 Mar 2018 | $9.36M | $3.41M – $25.7M | $12.8M (+37%) | before first round | – | unknown | D | 0% |
| 1 Apr 2018 | $9.62M | $3.50M – $26.4M | $13.2M (+37%) | before first round | – | unknown | D | 0% |
| 1 May 2018 | $9.87M | $3.59M – $27.1M | $13.5M (+37%) | before first round | – | unknown | D | 0% |
| 1 Jun 2018 | $10.1M | $3.69M – $27.8M | $13.9M (+37%) | before first round | – | unknown | D | 0% |
| 1 Jul 2018 | $10.4M | $3.79M – $28.6M | $14.3M (+37%) | before first round | – | unknown | D | 0% |
| 1 Aug 2018 | $10.7M | $3.89M – $29.4M | $14.4M (+35%) | before first round | – | unknown | D | 0% |
| 1 Sep 2018 | $11.0M | $4.00M – $30.2M | $14.5M (+32%) | before first round | – | unknown | D | 0% |
| 1 Oct 2018 | $11.3M | $4.10M – $30.9M | $14.7M (+30%) | before first round | – | unknown | D | 0% |
| 1 Nov 2018 | $11.6M | $4.21M – $31.8M | $14.8M (+28%) | before first round | – | unknown | D | 0% |
| 1 Dec 2018 | $27.6M | $24.0M – $57.1M | $49.7M (+80%) | after a round | – | unknown | B | 0% |
| 2 Dec 2018 | $27.6M | $24.0M – $57.1M | $49.7M (+80%) | after a round | – | unknown | B | 0% |
| 1 Jan 2019 | $29.0M | $24.0M – $57.1M | $49.7M (+71%) | after a round | – | unknown | B | 0% |
| 1 Feb 2019 | $30.5M | $24.0M – $57.1M | $49.7M (+63%) | after a round | – | unknown | B | 0% |
| 1 Mar 2019 | $31.9M | $24.0M – $57.1M | $49.7M (+56%) | after a round | – | unknown | B | 0% |
| 1 Apr 2019 | $33.5M | $24.0M – $57.1M | $49.7M (+48%) | after a round | – | unknown | B | 0% |
| 1 May 2019 | $35.2M | $24.0M – $57.1M | $49.7M (+41%) | after a round | – | unknown | B | 0% |
| 1 Jun 2019 | $37.0M | $24.0M – $57.1M | $49.7M (+34%) | after a round | – | unknown | B | 0% |
| 1 Jul 2019 | $38.8M | $24.0M – $57.1M | $49.7M (+28%) | after a round | – | unknown | B | 0% |
| 1 Aug 2019 | $40.8M | $24.0M – $57.1M | $49.7M (+22%) | after a round | – | unknown | B | 0% |
| 1 Sep 2019 | $42.9M | $24.0M – $57.1M | $49.7M (+16%) | after a round | – | unknown | B | 0% |
| 1 Oct 2019 | $45.0M | $24.0M – $57.1M | $49.7M (+10%) | after a round | – | unknown | B | 0% |
| 1 Nov 2019 | $47.3M | $24.0M – $57.1M | $49.7M (+5%) | after a round | – | unknown | B | 0% |
| 1 Dec 2019 | $49.7M | $24.0M – $57.1M | $49.7M (0%) | after a round | – | unknown | B | 0% |
| 1 Jan 2020 | $49.7M | $22.8M – $57.1M | $49.7M (0%) | after a round | – | unknown | B | 0% |
| 1 Feb 2020 | $49.7M | $21.7M – $57.1M | $49.7M (0%) | after a round | – | unknown | B | 0% |
| 1 Mar 2020 | $49.7M | $20.7M – $57.1M | $49.7M (0%) | after a round | – | unknown | B | 0% |
| 1 Apr 2020 | $49.7M | $19.6M – $57.1M | $49.7M (0%) | after a round | – | unknown | B | 0% |
| 1 May 2020 | $49.7M | $18.7M – $57.1M | $49.7M (0%) | after a round | – | unknown | B | 0% |
| 1 Jun 2020 | $49.7M | $17.8M – $57.1M | $49.7M (0%) | after a round | – | unknown | B | 0% |
| 1 Jul 2020 | $49.7M | $16.9M – $57.1M | $49.7M (0%) | after a round | – | unknown | C | 0% |
| 1 Aug 2020 | $49.7M | $16.1M – $57.1M | $49.7M (0%) | after a round | – | unknown | C | 0% |
| 13 Aug 2020 | $156M | $110M – $332M | $234M (+50%) | after a round | – | unknown | B | 0% |
| 1 Sep 2020 | $160M | $110M – $332M | $234M (+47%) | after a round | – | unknown | B | 0% |
| 1 Oct 2020 | $165M | $110M – $332M | $234M (+42%) | after a round | – | unknown | B | 0% |
| 1 Nov 2020 | $171M | $110M – $332M | $234M (+37%) | after a round | – | unknown | B | 0% |
| 1 Dec 2020 | $176M | $110M – $332M | $234M (+33%) | after a round | – | unknown | B | 0% |
| 1 Jan 2021 | $183M | $110M – $332M | $234M (+28%) | after a round | 78 | unknown | B | 0% |
| 1 Feb 2021 | $189M | $110M – $332M | $234M (+24%) | after a round | 78 | unknown | B | 0% |
| 1 Mar 2021 | $195M | $110M – $332M | $234M (+20%) | after a round | 78 | unknown | B | 0% |
| 1 Apr 2021 | $202M | $110M – $332M | $234M (+16%) | after a round | 78 | flat | B | 0% |
| 1 May 2021 | $209M | $110M – $332M | $234M (+12%) | after a round | 78 | flat | B | 0% |
| 1 Jun 2021 | $216M | $110M – $332M | $234M (+8%) | after a round | 78 | flat | B | 0% |
| 1 Jul 2021 | $223M | $110M – $332M | $234M (+5%) | after a round | 78 | flat | B | 0% |
| 1 Aug 2021 | $231M | $110M – $332M | $234M (+1%) | after a round | 78 | flat | B | 0% |
| 12 Aug 2021 | $2.2B | $1.9B – $3.3B | $2.9B (+30%) | after a round | 78 | flat | A | 0% |
| 1 Sep 2021 | $2.2B | $1.9B – $3.3B | $2.9B (+28%) | after a round | 78 | flat | A | 0% |
| 1 Oct 2021 | $2.3B | $1.9B – $3.3B | $2.9B (+25%) | after a round | 78 | flat | A | 0% |
| 1 Nov 2021 | $2.3B | $1.9B – $3.3B | $2.9B (+23%) | after a round | 78 | flat | A | 0% |
| 1 Dec 2021 | $2.4B | $1.9B – $3.3B | $2.9B (+20%) | after a round | 78 | flat | A | 0% |
| 1 Jan 2022 | $2.4B | $1.9B – $3.3B | $2.9B (+17%) | after a round | 78 | flat | A | 0% |
| 1 Feb 2022 | $2.5B | $1.9B – $3.3B | $2.9B (+15%) | after a round | 78 | flat | A | 0% |
| 1 Mar 2022 | $2.5B | $1.9B – $3.3B | $2.9B (+12%) | after a round | 78 | flat | A | 0% |
| 1 Apr 2022 | $2.6B | $1.9B – $3.3B | $2.9B (+10%) | after a round | 78 | flat | A | 0% |
| 22 Apr 2022 | $4.8B | $4.2B – $7.2B | $6.2B (+30%) | after a round | 78 | flat | A | 0% |
| 1 May 2022 | $4.8B | $4.2B – $7.2B | $6.2B (+29%) | after a round | 78 | flat | A | 0% |
| 1 Jun 2022 | $4.9B | $4.2B – $7.2B | $6.2B (+26%) | after a round | 78 | flat | A | 0% |
| 1 Jul 2022 | $5.1B | $4.2B – $7.2B | $6.2B (+24%) | after a round | 78 | flat | A | 0% |
| 1 Aug 2022 | $5.2B | $4.2B – $7.2B | $6.2B (+21%) | after a round | 78 | unknown | A | 0% |
| 1 Sep 2022 | $5.3B | $4.2B – $7.2B | $6.2B (+18%) | after a round | 78 | unknown | A | 0% |
| 1 Oct 2022 | $5.4B | $4.2B – $7.2B | $6.2B (+16%) | after a round | 78 | unknown | A | 0% |
| 1 Nov 2022 | $5.5B | $4.2B – $7.2B | $6.2B (+13%) | after a round | 98 | unknown | A | 0% |
| 1 Dec 2022 | $5.6B | $4.2B – $7.2B | $6.2B (+11%) | after a round | 98 | unknown | A | 0% |
| 1 Jan 2023 | $5.8B | $4.2B – $7.2B | $6.2B (+8%) | after a round | 98 | unknown | A | 0% |
| 1 Feb 2023 | $5.9B | $4.2B – $7.2B | $6.2B (+6%) | after a round | 98 | unknown | A | 0% |
| 1 Mar 2023 | $6.0B | $4.2B – $7.2B | $6.2B (+4%) | after a round | 98 | unknown | A | 0% |
| 1 Apr 2023 | $6.1B | $4.2B – $7.2B | $6.2B (+1%) | after a round | 98 | unknown | A | 0% |
| 1 May 2023 | $6.2B | $4.1B – $7.2B | $6.2B (0%) | after a round | 98 | unknown | A | 0% |
| 1 Jun 2023 | $6.2B | $3.9B – $7.2B | $6.2B (0%) | after a round | 98 | unknown | B | 0% |
| 1 Jul 2023 | $6.2B | $3.8B – $7.2B | $6.2B (0%) | after a round | 98 | unknown | B | 0% |
| 1 Aug 2023 | $6.2B | $3.6B – $7.2B | $6.2B (0%) | after a round | 98 | unknown | B | 0% |
| 1 Sep 2023 | $6.2B | $3.4B – $7.2B | $6.2B (0%) | after a round | 98 | unknown | B | 0% |
| 1 Oct 2023 | $4.3B | $3.2B – $5.9B | $3.2B (-26%) | after a round | 76 | down | B | 97% |
| 1 Nov 2023 | $4.2B | $3.0B – $6.0B | $3.1B (-27%) | after a round | 76 | down | B | 97% |
| 1 Dec 2023 | $4.1B | $2.9B – $6.0B | $3.0B (-27%) | after a round | 76 | down | B | 97% |
| 1 Jan 2024 | $4.0B | $2.7B – $6.1B | $3.0B (-27%) | after a round | 76 | down | B | 97% |
| 1 Feb 2024 | $4.0B | $2.6B – $6.1B | $2.9B (-27%) | after a round | 76 | down | B | 97% |
| 1 Mar 2024 | $3.9B | $2.5B – $6.2B | $2.8B (-27%) | after a round | 75 | down | B | 97% |
| 1 Apr 2024 | $3.8B | $2.4B – $6.3B | $2.8B (-28%) | after a round | 75 | down | B | 97% |
| 1 May 2024 | $3.6B | $2.3B – $6.3B | $2.4B (-33%) | after a round | 75 | down | B | 97% |
| 1 Jun 2024 | $3.7B | $2.1B – $6.5B | $2.5B (-31%) | after a round | 75 | flat | B | 89% |
| 1 Jul 2024 | $3.8B | $2.0B – $6.6B | $2.6B (-30%) | after a round | 72 | flat | B | 82% |
| 1 Aug 2024 | $3.8B | $1.9B – $6.7B | $2.7B (-28%) | after a round | 73 | flat | C | 76% |
| 1 Sep 2024 | $3.9B | $1.8B – $6.8B | $2.8B (-27%) | after a round | 73 | flat | C | 70% |
| 1 Oct 2024 | $4.0B | $1.8B – $6.9B | $3.0B (-26%) | after a round | 73 | flat | C | 64% |
| 1 Nov 2024 | $4.1B | $1.7B – $6.9B | $3.1B (-25%) | after a round | 71 | flat | C | 59% |
| 1 Dec 2024 | $4.2B | $1.6B – $7.0B | $3.1B (-24%) | after a round | 71 | flat | C | 54% |
| 1 Jan 2025 | $4.3B | $1.5B – $7.0B | $3.2B (-24%) | after a round | 71 | flat | C | 50% |
| 1 Feb 2025 | $4.3B | $1.4B – $7.1B | $3.3B (-23%) | after a round | 71 | flat | C | 46% |
| 1 Mar 2025 | $4.4B | $1.4B – $7.1B | $3.4B (-23%) | after a round | 71 | flat | C | 42% |
| 1 Apr 2025 | $4.5B | $1.3B – $7.2B | $3.5B (-22%) | after a round | 71 | flat | C | 39% |
| 1 May 2025 | $4.4B | $1.2B – $7.2B | $3.5B (-21%) | after a round | 71 | flat | C | 36% |
| 1 Jun 2025 | $4.4B | $1.2B – $7.1B | $3.6B (-20%) | after a round | 71 | flat | C | 33% |
| 1 Jul 2025 | $4.5B | $1.1B – $7.1B | $3.6B (-19%) | after a round | 71 | flat | C | 30% |
| 1 Aug 2025 | $4.5B | $1.1B – $7.1B | $3.7B (-18%) | after a round | 78 | flat | C | 28% |
| 1 Sep 2025 | $4.6B | $1.0B – $7.0B | $3.8B (-17%) | after a round | 78 | flat | C | 26% |
| 1 Oct 2025 | $4.6B | $961M – $7.0B | $3.9B (-16%) | after a round | 77 | flat | C | 24% |
| 1 Nov 2025 | $4.7B | $913M – $6.9B | $4.0B (-15%) | after a round | 75 | flat | D | 22% |
| 1 Dec 2025 | $4.7B | $870M – $6.9B | $4.0B (-15%) | after a round | 75 | flat | D | 20% |
| 1 Jan 2026 | $4.8B | $826M – $6.9B | $4.1B (-14%) | after a round | 75 | flat | D | 18% |
| 1 Feb 2026 | $4.8B | $785M – $6.8B | $4.1B (-14%) | after a round | 75 | flat | D | 17% |
| 1 Mar 2026 | $4.8B | $750M – $6.8B | $4.2B (-13%) | after a round | 75 | flat | D | 16% |
| 1 Apr 2026 | $4.8B | $713M – $6.8B | $4.3B (-12%) | after a round | 75 | flat | D | 14% |
| 1 May 2026 | $4.8B | $679M – $6.7B | $4.4B (-10%) | after a round | 78 | flat | D | 13% |
| 1 Jun 2026 | $4.8B | $645M – $6.5B | $4.3B (-11%) | after a round | 78 | flat | D | 11% |
| 1 Jul 2026 | $4.8B | $614M – $6.5B | $4.3B (-11%) | after a round | 78 | flat | D | 10% |
| 1 Aug 2026 | $4.8B | $583M – $6.4B | $4.3B (-10%) | after a round | 78 | flat | D | 9% |
| 1 Sep 2026 | $4.8B | $554M – $6.4B | $4.4B (-10%) | after a round | 78 | flat | D | 8% |
| 1 Oct 2026 | $4.8B | $528M – $6.3B | $4.4B (-9%) | after a round | 78 | flat | D | 8% |
| 24 Oct 2026 | $3.2B | $341M – $6.3B | $3.0B (-8%) | after a round | 78 | flat | D | 8% |
Key facts about OneStudyTeam
- Founded
- 2012
- Headquarters
- Boston, United States
- Employees
- about 78 +1% in a year
- Total raised
- $477M
- Funding rounds
- 4
- Last round
- Series D Apr 2022
OneStudyTeam was founded in 2012 by Michael Lin and Ralph Passarella.
OneStudyTeam funding history
OneStudyTeam has 4 funding rounds on record, from Dec 2018 to Apr 2022, $477M in total. The latest disclosed valuation is $4.80B post-money (Series D, Apr 2022).
Series D 21 Apr 2022
Led by Altimeter, Coatue; with Dragoneer Investment Group, ICONIQ Growth, Adams Street Partners, Battery Ventures.
Sources: finsmes.com, ispeboston.org, mobihealthnews.com and 4 more
$220M
$4.80B post-money
Series C 11 Aug 2021
Led by Coatue; with ICONIQ Capital, Adams Street Partners, Sierra Ventures, Battery Ventures.
Sources: finsmes.com, fiercebiotech.com
$220M
$2.20B post-money
Series B 12 Aug 2020
Led by Battery Ventures; with Sierra Ventures, Asset Management Ventures.
Sources: finsmes.com, mobihealthnews.com
$30M
$7.4M
$28M post-money
OneStudyTeam investors
9 investors have backed OneStudyTeam; Battery Ventures, Coatue and Altimeter led at least one round.
- Battery Ventures lead, 3 rounds
- Coatue lead, 2 rounds
- Altimeter lead
- Sierra Ventures 3 rounds
- Adams Street Partners 2 rounds
- Dragoneer Investment Group
- ICONIQ Capital
- ICONIQ Growth
What OneStudyTeam does
OneStudyTeam works in tech companies, with 14 recorded offerings and customers in healthcare and biopharmaceuticals.
Reify Health, Inc., known as OneStudyTeam, is an American software company that develops cloud-based solutions for clinical trials. The company provides a platform that integrates research site workflows with sponsor systems, supporting functions such as data analysis, recruitment vendor management, and site performance reporting. OneStudyTeam also offers machine learning and AI-assisted tools to support clinical research activities. Its solutions are used by biopharmaceutical companies, research clinics, and healthcare organizations in over 100 countries, with operations in the United States, Europe, and Japan.
Description from Veridion's company data.
Products and services
- Clinical Trial Management Software Development
- Clinical Trial Workflow Integration Solutions
- Patient Enrollment Optimization Solutions
- Research Site Collaboration Tools Development
- Clinical Data Analysis and Reporting Solutions
- Recruitment Vendor Management Solutions
- Site Performance Insights and Analytics
- Diversity Participation Reporting Solutions
- Recruitment Slot Management Solutions
- AI-Driven Clinical Research Solutions
- Clinical Trial Infrastructure Deployment
- Clinical Trial Scalability and Integration Services
- Multilingual Clinical Trial Software Services
- Clinical Research Collaboration Services
Markets
- Healthcare
- Biopharmaceuticals
Technology
- Machine Learning for Clinical Research
- AI-Assisted Clinical Research
Business model
- Business-to-Business
- Software-as-a-Service
- Enterprise
Industry codes (NAICS)
- 513210 Software Publishers 100% match
Questions about OneStudyTeam
What is OneStudyTeam worth?
Valuation $3.2B (range $341M to $6.3B), as of 24 Oct 2026. The last disclosed valuation was $4.80B (Series D, Apr 2022).
Has OneStudyTeam raised money?
OneStudyTeam has 4 funding rounds on record, from Dec 2018 to Apr 2022, $477M in total. The latest disclosed valuation is $4.80B post-money (Series D, Apr 2022).
Who has invested in OneStudyTeam?
Battery Ventures, Coatue, Altimeter, Sierra Ventures, Adams Street Partners and Asset Management Ventures, and 3 more. Lead investors include Battery Ventures, Coatue and Altimeter.
How many people work at OneStudyTeam?
About 78, up 1% over the last year. Headcount rose from 78 in Jan 2021 to 98 in Nov 2022, then fell to 78 in Sep 2026.
What does OneStudyTeam do?
OneStudyTeam works in tech companies, with 14 recorded offerings and customers in healthcare and biopharmaceuticals. Its main offerings are clinical trial management software development, clinical trial workflow integration solutions and patient enrollment optimization solutions.
When was OneStudyTeam founded, and where is it based?
OneStudyTeam was founded in 2012 and is based in Boston, United States. It has about 78 employees, up 1% over the last year.